Jeff Hall

In a recent interview, Constance Lehman, MD, PhD, discussed newly published research demonstrating the dynamic capability of AI-based risk scores, drawn from screening mammograms, to facilitate risk-adaptive screening.

In a recent episode of our “Molecular Imaging in Focus” series, Surekha Yadav, MBBS, MD, discussed research presented at the SNMMI conference that showed significant advantages of PSMA PET over conventional imaging for detection of osseous oligometastatic prostate cancer (PCa).

The VascularAssist Occlusion Triage software reportedly demonstrated over a 90 percent sensitivity for detecting peripheral artery disease (PAD) on CT in clinical performance testing.

Catch up on the top radiology content of the past week.

The use of FAPI PET/CT offered a 97 percent pooled sensitivity for detecting peritoneal metastases in a patient-based analysis in a new meta-analysis involving over 800 patients.

For patients with advanced melanoma, the melanin-targeted PET radiotracer (¹⁸F)DMPY2 offered superior detection of metastatic foci in the brain and liver in comparison to (¹⁸F)FDG, according to preliminary comparative research presented at the recent SNMMI conference.

In a recent interview, Mary L. Bouxsein, PhD, discussed challenges with access to dual-energy X-ray absorptiometry (DEXA) screening for osteoporosis, the emergence of biomechanical CT (BCT) and the potential impact of national Medicare coverage of BCT for bone mass measurement.

For pancreatic cancers less than or equal to 20 mm, a deep learning model offered a nearly 45 percent higher sensitivity rate with non-contrast CT in comparison to unassisted radiologist interpretation.

In the latest episode of the Molecular Imaging in Focus series, Michael Hofman, MBBS, FRACP, discussed the potential of an emerging PET radiotracer for DVT detection spotlighted in SNMMI’s “Image of the Year,” a new advance in total body PET/CT and other highlights from the SNMMI conference.

While use of an AI software demonstrated significantly higher accuracy in evaluating BI-RADS 2 presentations and no significant difference with radiologists in BI-RADS 4 assessments of breast ultrasound in a sub-analysis, researchers noted the exclusion of galactoceles, fluid collections and skin lesions that are commonly found in pregnant and lactating women.

In a recent interview, new SNMMI president Heather Jacene, MD, discussed key goals for bolstering workforce development in nuclear medicine, improving infrastructure equity and optimizing emerging advances to facilitate precision treatments in oncology.

Indicated for the detection and visualization of abnormal vascularity in the central nervous system (CNS) and non-CNS body regions, gadoquatrane provides 60 percent less gadolinium dosing in comparison to other macrocyclic gadolinium (Gd)-based contrast agents (mGBCAs).

Catch up on the top radiology content of the past week.

In a recent interview, Nina Kottler, MD, discussed the challenges with traditional radiology reporting, its impact on cognitive load and the recently launched AI-enabled platform Mosaic Reporting.

For men with high clinical risk for prostate cancer (PCa) and a lack of significant findings on mpMRI, triage use of PSMA PET/CT resulted in a 49 percent reduction of biopsies and an 18 percent reduction in detection of clinically insignificant PCa, according to newly published research.

The AI-enabled image processing with SubtleHD(CT) software reportedly facilitates improved noise reduction and image quality for computed tomography (CT) exams.

The Reporting Pro software reportedly offers an array of AI-enabled features that may help streamline radiology reports.

In a new survey of over 2,000 health-care professionals on AI use, respondents cited benefits ranging from improved work-life balance to preventing medical errors as well as concerns about overreliance on AI and inconsistent or limited training.

In recent interviews, Emanuel Kanal, MD, and Tobias Gilk, MRSO, MRSE, noted a lack of point-of-care safety requirements for MRI, a lack of state oversight, and a prevailing lack of minimum standards overall for MRI safety.

Preoperative use of (68Ga)Ga-FAPI-46 PET/CT demonstrated an 81 percent intraclass correlation coefficient (ICC) with the intraoperative peritoneal cancer index (PCI) in comparison to 76 percent for MRI and 54 percent for (18F)FDG PET/CT (FDG PET), according to new research presented at the SNMMI conference.

The proportion of breast cancer potentially flagged by three different AI algorithms 10 years prior to diagnosis ranged between 12.7 to 17 percent, according to newly published retrospective research.

Use of the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide led to a > 30 percent reduction in liver fat content in nearly 85 percent of obese patients with at-risk MASLD, according to MRI findings in new phase 3 research.

Catch up on the top radiology content of the past week.

While researchers saw no significant difference in metastasis-free survival with the use of perioperative apalutamide in patients undergoing radical prostatectomy based on conventional imaging alone, the addition of PSMA PET imaging revealed a 20 percent higher likelihood of metastasis-free survival with adjunctive apalutamide.

The MIM Contour ProtegeAI+ 2.0 software reportedly offers new AI-powered contouring models for brain MRIs and pelvic CTs.

In comparison to short-axial field of view PET/CT scanners, a total body PET/CT imaging platform with a long axis field of view detected more lesions in 68 percent of patients while reducing scan times by 83 percent, according to new research presented at the SNMMI conference.

In a recent interview, Phillip Kuo, MD, discussed new comparative multicenter prospective research, presented at the SNMMI conference, examining the urinary radioactivity of two PSMA PET radiotracers 18F-piflufolastat and 18F-flotufolastat.

Prior vaccination for prostate cancer-specific antigens was associated with more than double the rate of two-year overall survival in patients with mCRPC who were treated with 177Lu-PSMA-617, according to new research presented at the SNMMI conference.

Preliminary research findings, presented at the SNMMI conference, suggest that the alpha-emitting radioconjugate ATNM-400 may be a viable alternative for treating PCa that is resistant to androgen receptor pathway inhibitors (ARPIs).

Noting the potential for workload efficiencies in interpreting screening digital breast tomosynthesis (DBT) images, researchers found the use of slab reconstruction technology improved specificity without any impact on sensitivity or cancer detection rate.